Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. Top Stock Analyzer Message Board

$PBIO Dr. Alexander Lazarev, PBI's Chief Scientifi

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 10156
(Total Views: 134)
Posted On: 08/17/2020 3:06:25 PM
Avatar
Posted By: Lets Roll
$PBIO Dr. Alexander Lazarev, PBI's Chief Scientific Officer, said: "This long-anticipated patent is an exciting endorsement of our efforts to transform biological sample preparation. Our PCT sample preparation workflows have been adopted not only in biomarker discovery and cancer research, but they are now advancing into enormous opportunities in clinical applications. More recently, PCT is now opening major opportunities in the biopharmaceutical development and manufacturing markets, ranging from protein characterization and quality control to bioprocess development, protein refolding and formulations development. Single use MicroPestle consumables enable research in all of these markets, and this powerful new dimension to our patent protected portfolio should help us to secure and accelerate the growth of our business."

Mr. Richard T. Schumacher, President and CEO of PBI, added: "This is a critical patent award and important news for PBI. The PCT MicroPestle consumable is integral to our current and future PCT expansion plans. Scientists worldwide continue to generate strong data showing that they can generate the highest quality analytical results by using the PCT MicroPestle, especially in the preparation of precious biopsy samples for analysis of biomarkers to diagnose disease and guide treatment selections. With the PCT MP patent now in hand, we have materially strengthened our intellectual property platform. We believe the newly patented PCT MP consumable will help drive sales of PCT systems into many new customer sites and applications globally."

https://www.otcmarkets.com/stock/PBIO/news/Pr...?id=270569


(0)
(0)




Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!




Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us